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Introduction
Ovarian cancer is the sixth most frequent female can-
cer type and the sixth most frequent cause of death
from cancer among women in Poland. Approximately
2700 new cases appear every year, constituting an age-
standardized incidence rate of 14,4 per 100 000, which
is one of the highest incidence rates observed world-
wide [1].
Most human malignancies are the end result of an
accumulation of mutations within tumor-suppressor
genes and oncogenes as well as of the dysregulation of
specific genes resulting in the antiapoptotic proteins
eliminations [2]. Molecular studies have identified
several genetic alterations such as p53, KRAS, c-erB-2,
PTEN, HER-2/neu and BRCA1 mutations in ovarian
tumors [3,4].
The RAS family of oncogenes is constituted of
three principal members -KRAS, HRAS and NRAS – all
of which have been implicated in the development of
human malignancies. The KRAS oncogene resides on
chromosome 12p12 and encodes a 21-kD protein
(p21RAS) involved in the MAP-kinase signal trans-
duction pathway, modulating cellular proliferation and
differentiation. Mutations of the KRAS oncogene result
in constitutive activation of this signal transduction
pathway and consequently unregulated proliferation
and impaired differentiation [5,6]. 
Activation of RAS oncogenes also occurs in ovari-
an tumors. Some studies have shown that KRAS muta-
tions are more frequent in mucinous than in nonmuci-
nous neoplasm [7-9], whereas other studies have not
revealed correlation with histological type [10]. All the
reported studies are based on a relatively small number
of patients and therefore, the results remain a subject
of debate.
In this study, we analyzed the presence of muta-
tions at codon 12 of the KRAS gene in 78 ovarian
tumors by using a restriction fragment length poly-
morphism-polymerase chain reaction technique
(RFLP-PCR) and we evaluated whether such alter-
ations correlated with the selected clinicopathological
parameters of the patients.
Materials and methods
In this study, we analyzed the presence of mutations at codon 12 of
the KRAS gene in 78 women with ovarian tumor, including 64
invasive ovarian cancers and 14 borderline ovarian tumors. All
tumors were staged according to the criteria of the International
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Federation of Gynecology and Obstetrics (FIGO). The median age
of the patients was 58 (range, 34-75) years. The protocol was pre-
viously approved by the Bioethical Committee of the Medical
University of Bia³ystok (R-I-003/206/2004). 
Serial paraffin sections were stained with H&E for light micro-
scopic study. Clinicopathological information was obtained from
medical charts. Histopathological examination was performed
according to the WHO classification. Tissues were immediately
frozen in liquid nitrogen after operation and stored at -80°C until
use. We microscopically confirmed that the tumor specimens con-
sisted mainly of carcinoma tissue (80%). DNA extraction was per-
formed with a "GeneElute Mammalian Genomic DNA Miniprep
Kit" (Sigma), according to the manufacturer's instructions. Before
DNA extraction, tumor samples (30 – 50 mg) were minced by the
use of a sterile scalpel and then digested for overnight at 37°C in
180 μl of tissue lysis buffer from the kit, containing 20 μl of pro-
teinase K solution (10 mg/ml). Isolated DNA was stored at -20°C
before further assays. 
The detection of KRAS mutations at codon 12 was performed
by PCR-RFLP method and the results of the detection were veri-
fied by direct sequencing of PCR products. DNA amplification was
performed in 20 μl reaction mixture containing 10 – 100 ng of
genomic DNA isolated from tissue, 1.5 mM of MgCl2, 0,2 mM of
dNTPs (Sigma), 0.2  M of each of the primers K1 and DD5P and
1,0 U of Taq DNA polymerase (Sigma) in 1× PCR buffer supplied
by the polymerase manufacturer. The K1 upstream primer (5'-
ACT GAA TAT AAA CTT GTG GTA GTT GGA CCT -3') was
immediately upstream of K-RAS codon 12 and introduced a G to C
substitution at the first position of the codon 11 of K-RAS in order
to create a BstOI restriction site (5'-CCT/AGG-3') within the above
amplified fragment which overlapped the first two nucleotides of
codon 12 and was lost when codon 12 mutations took place. The
downstream primer DD5P was as follows: 5'-TCA TGAAAA TGG
TCA GAG AA-3'. 
After the initial DNA denaturation at 95°C for 3 min, PCR was
carried out for 40 cycles (94°C for 15 s, 56°C for 15 s, 72°C for 15 s)
followed by terminal extension of PCR products at 72°C for 7 min-
utes. PCR products were then digested with a restriction endonu-
clease BstOI. For this purpose, five-microliter aliquots of the post-
PCR reaction mixture were digested with 10 U of the restriction
endonuclease BstOI (PROMEGA) in the appropriate reaction
buffer (supplied by the enzyme manufacturer) in the final volume
of 10 μl at 60°C for 3 h. The additional aliquot of 5 U of the
enzyme was added to the reaction mixture after the first hour of the
digestion. The enzyme recognized the sequence 5'-CCTGG-3',
which was present in codon 12 KRAS wild type PCR products, but
was absent from the mutant ones. As a result, only the wild type
molecules were digested into two fragments – 160 bp and 29 bp
long. The digestion products were then electrophoresed on a 6%
native polyacrylamide gel, stained with ethidium bromide and pho-
tographed on a ultraviolet light transilluminator with the use of
UVI-KS 400i/Image PC system. The non-restricted PCR products
were 189 bp long, whereas the wild type codon 12 products, being
restricted inside codon 12 sequence, were 160 bp long. 
All mutations were then confirmed by direct sequencing of the
PCR products. For this purpose, antisense strain of PCR products
were sequenced with the antisense primer DD5P, an ABI PRISM
BigDye Terminator v.3.1 Cycle Sequencing Ready Reaction
(Applied Biosystems) and an automatic ABI PRISM 377 DNA
sequencer (Applied Biosystems). A wild-type control DNA sample
(without KRAS codon 12 mutation) and a known mutation sample
were included in all the experiments. All experiments were dupli-
cated precisely. For statistical analysis, the χ2 test was performed;
p<0.01 was considered significant.
Results
The age of the patients ranged from 34 to 75 years
(mean, 58). KRAS gene mutations at codon 12 in tumor
tissue were detected in 4 of 64 (6.2%) cases with pri-
mary invasive ovarian carcinomas and in 2 of 14
(14,3%) cases with a borderline ovarian tumor (Fig. 1).
We detected KRAS gene mutation in 1 of 36 serous
adenocarcinomas (2.7%), 3 of 13 mucinous adenocar-
cinomas (23%) and 2 of 14 borderline ovarian tumors
(14.3%). No mutations were detected in undifferentiat-
ed carcinomas, papillary adenocarcinomas, endometri-
oid adenocarcinomas, nonepithelial carcinomas and in
clear cell neoplasms (Table 1, 2). 
Overall, a KRAS codon 12 point mutation was
detected in approximately 10% (8/78) of the examined
tumors and did not correlate with the malignant poten-
tials (e.g. stage and grade) and patients' age (Table 1).
There was a tendency towards a higher incidence of
KRAS mutations in the mucinous tumors – 23% (3/13)
than in the borderline and serous tumors – 14.3%
(2/14) and 2.7% (1/36), respectively. These statistical
differences are significant (p<0.01). 
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Fig. 1. Examples of mutation analysis of KRAS gene. (A)  KRAS codon 12 restriction fragment length polymorphism analysis. (B) A
sequencing electropherograms with KRAS codon 12 mutants.  (←) mutation in KRAS gene, (*) a mismatch base in artificial forward
primer, SM, size marker; WT, wild type, M, mutant.
Discussion
Epithelial ovarian tumors are a complex clinical, diag-
nostic and therapeutic challenge because of the diffi-
culty of early detection, lack of known precursor
lesions and high mortality rates. Advanced-stage dis-
ease display aggressive chemoresistant behavior with
patients demonstrating a shorter median survival rate
[11,12]. 
Extensive studies have been performed on human
samples assessing the presence of activated forms of
KRAS in numerous malignant neoplasms, e.g.: pan-
creas (60%), biliary tract (32%), large intestine (32%),
small intestine (20%), gastrointestinal tract (site inde-
terminate) (19%), thymus (15%) and endometrium
(14%) [13].
In epithelial ovarian cancers, the incidence of
KRAS point mutations is between 15% and 39%
[13,14]. In our study KRAS mutation frequencies seem
to be highly related to tumor histology. There was a
tendency towards a higher incidence of KRAS muta-
tion in the mucinous tumors (23%) than in the border-
line and serous tumors (14.3% and 2.7%), respective-
ly. In general, KRAS mutations occur more frequently
in mucinous tumors, including borderline malignan-
cies, than in nonmucinous tumors such as serous car-
cinomas. Thus, point mutations in the KRAS gene
seem to be more commonly associated with mucinous
carcinomas [15]. 
Our earlier study showed that mucinous borderline
tumors are clearly distinct from their serous counter-
parts [16,17]. In this study we found that more muci-
nous ovarian tumors have KRAS mutations than bor-
derline tumors and other invasive cancers. Thus, both
mucinous ovarian cancer and borderline ovarian tumor
are basically different from other ovarian cancers since
the former are initiated by specific mutations (e.g.
KRAS ) while the latter are initiated by different mech-
anisms [18].
A few previous studies have determined the prog-
nostic role of KRAS alteration in ovarian cancer [19].
Several studies found no correlation between KRAS
gene mutations and survival [10,20], while very few
concluded that there is a significant negative relation-
ship using multivariate analysis [21].
We found 3/13 of the investigated mucinous ovari-
an cancer tissues (23%) to have a mutation in KRAS
codon 12, which was the highest frequency detected in
a subgroup of patients in this study, and significantly
higher than the frequency of 1/36 for serous adenocar-
cinomas (2.7%). All the two borderline ovarian tumors
(2/14) found to have a mutation in KRAS codon 12
were mucinous (14.3%). Thus, KRAS mutations fre-
quency in our study was correlated with the histologi-
cal type of tumor but not with other clinicopathologi-
cal parameters such as grade, stage or patients age. 
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Table 1. Distribution of KRAS mutations according to clinico-
pathological characteristics of the examined ovarian lesions.
Table 2. KRAS gene mutations in the examined ovarian lesions.
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